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Introduction {#cam4965-sec-0001}
============

Lung cancer is a significant health problem worldwide and the most common cause of cancer death in the industrialized world [1](#cam4965-bib-0001){ref-type="ref"}. In Denmark, lung cancer comprises 12% of all new cancer cases [2](#cam4965-bib-0002){ref-type="ref"}. Survival from lung cancer is related to the stage of disease, and 5‐year survival is 50% for localized lung cancer and 2% for a lung cancer with distant spread. Earlier diagnosis of lung cancer may be beneficial in allowing more lung cancer patients curative treatment. Danish lung cancer patients have lower survival than patients from comparable European countries [3](#cam4965-bib-0003){ref-type="ref"}, [4](#cam4965-bib-0004){ref-type="ref"}. This can possibly be explained by later diagnosis of lung cancer in Denmark and research indicates a lower proportion of lung cancer patients in curable stage in Denmark compared to Norway and Sweden [5](#cam4965-bib-0005){ref-type="ref"}. Thus, it is possible that the survival deficit in Danish patients may relate to processes of cancer awareness and diagnostic activity at the level of primary care. Delay in diagnosis before admission to a hospital can be due to either patients delaying going to the general practitioner (GP) (the so called patient\'s interval) or the GP delaying referral (doctor\'s interval). This warrants scrutiny of the diagnostic pathway in Danish lung cancer patients.

Most lung cancer patients present with a range of symptoms to the GP in the months before diagnosis [6](#cam4965-bib-0006){ref-type="ref"}, [7](#cam4965-bib-0007){ref-type="ref"}, [8](#cam4965-bib-0008){ref-type="ref"}, [9](#cam4965-bib-0009){ref-type="ref"}. The symptoms, such as cough and breathlessness, are relatively common in the general population [10](#cam4965-bib-0010){ref-type="ref"}, and alarm symptoms for lung cancer have low‐positive predictive values [11](#cam4965-bib-0011){ref-type="ref"}. Symptoms and signs from lung cancer can mimic common diseases such as chronic obstructive pulmonary disease (COPD), leading to a risk for delayed diagnosis [12](#cam4965-bib-0012){ref-type="ref"}.

Only a third of lung cancer patients present to GPs with an alarm symptom (such as prolonged coughing, hemoptysis, or weight loss) [12](#cam4965-bib-0012){ref-type="ref"} which is the entrance criterion for the urgent referral route for lung cancer. The PPVs for such symptoms are, depending on the patient\'s age, between 1% and 4.5%.

Consequently, only 25% of all lung cancer patients are diagnosed through this route [12](#cam4965-bib-0012){ref-type="ref"}, [13](#cam4965-bib-0013){ref-type="ref"}. There seems to be a need for other referral options for this group of patients. For persons who were later diagnosed with lung cancer we quantified the prediagnostic activity in general practice along with a matched comparison group, and we compared the activity between lung cancer patients with different stage, and between lung cancer patients with and without COPD.

Methods {#cam4965-sec-0002}
=======

Study design and study population {#cam4965-sec-0003}
---------------------------------

In Denmark (5.6 million inhabitants), 4560 new lung cancer cases are diagnosed yearly. The age‐standardized (World standard population) lung cancer incidence rates for men and women were 49.9 and 36.7, respectively, with a 1.4% decrease for men and 0.1% increase for women during the study period. We performed a population‐based matched cohort study using register data. Information was collected from nationwide registers at individual level using the unique civil registration number assigned to all Danish residents [14](#cam4965-bib-0014){ref-type="ref"}. In Denmark, GPs are gatekeepers to the rest of the health care system and 98% of citizens are listed with a general practice and have free access. GPs are remunerated based on a mixed capitation and fee‐for‐service (25/75%) which ensures complete registration of their services.

### Lung cancer patients {#cam4965-sec-0004}

Patients diagnosed with lung cancer (according to the International Classification of Diseases, ICD‐10 C34) from 1 January 2003 to 31 December 2012 (*n* = 36,342) in Denmark were identified in the Danish Cancer Registry (DCR) and the Danish Lung Cancer Registry (DLCR). The DCR is a national register of all Danish cancer patients and holds information on date of diagnosis (ICD‐10), anatomical site, morphology, and stage. If a patient develops more than one primary cancer, each cancer is registered as a separate record. In the DCR, information about tumor stage at diagnosis is provided by a multidisciplinary team decision, it contains both cTNM and pTNM if available. Reporting to the DCR became mandatory in 1987 [15](#cam4965-bib-0015){ref-type="ref"}. The DLCR was established in 2001. It contains clinical information about Danish lung cancer patients such as lung function, smoking history, and stage, which are combined with data on cancer treatment and follow‐up. In the DLCR, information about tumor stage at diagnosis is provided by a multidisciplinary team decision with one TNM stage (which can be either cTNM or pTNM). Since 2003, the DLCR includes data on more than 90% of all lung cancer cases in Denmark [16](#cam4965-bib-0016){ref-type="ref"}.

Lung cancer patients were excluded from the analyses if they had an incorrect civil registration number (*n* = 398 \[1.1%\]), had lived outside Denmark at some point during the 12 months preceding the diagnosis (*n* = 670 \[1.8%\]) or were not listed with a general practice (*n* = 672 \[1.8%\]). We furthermore excluded 163 (0.5%) patients aged less than 40 years and 202 (0.6%) patients aged more than 90 years.

### The comparison cohort {#cam4965-sec-0005}

Ten comparison subjects were selected for each patient. They matched the lung cancer patient on year of birth, gender and were listed with the same general practice as the lung cancer patients at time of diagnosis (index date). As for patients, these persons were ineligible if they had been living outside Denmark at some point during the 12 months before the index date. Patients and comparison subjects could have no record of any cancer in the DCR at the time of the index date (except nonmelanoma skin cancer).

We excluded 220 (0.6%) lung cancer patients which we were not able to match with comparison subjects. This left 34,017 lung cancer patients for analysis.

Prediagnostic activity {#cam4965-sec-0006}
----------------------

In order to estimate the prediagnostic health care activity for patients, we selected a range of diagnostic test or treatments made in general practice that a GP would use if a patient presented with pulmonary symptoms.

Data sources {#cam4965-sec-0007}
------------

Information about general practice enrolment was available from the Patient List Register, which is an administrative database that holds information on which general practice each person is listed with at any given time.

### Activity in general practice {#cam4965-sec-0008}

The Danish National Health Service Registry (HSR) was used to gather information about contacts in general practice [17](#cam4965-bib-0017){ref-type="ref"}. Face‐to‐face consultations, home visits and telephone contacts during daytime were included. HSR was also used to obtain information about numbers and dates of lung function tests performed in general practice. The tests included: extended lung function test with spirometry (activity code: 7113), double lung function test for exercise‐induced asthma (7121) and peak flow (7183).

The prescriptions of medicines for respiratory diseases and infections were collected from the Danish National Prescription Registry (DNPR) [18](#cam4965-bib-0018){ref-type="ref"}. The products included: adrenergic (ATC: R03AC, R03CC), adrenergic and glucocorticoids (RO3AK) anticholinergics (R03BB), theophylline (R03DA), glucocorticoids, systemic (H02AB), leukotrienes (R03DC), glucocorticoids, inhalation (R03BA), penicillin (J01C), and tetracycline (J01AA). These medicines are all available by prescription only.

In the analyses we focused on new or first‐time prescriptions redeemed and lung function test performed in the 12 months before diagnosis; that is, that it was only included if there had been no prescription redeemed or lung function test performed in the period between 12 and 36 months before lung cancer diagnosis.

Data on radiology procedures were obtained from the HSR and the Danish National Patient Registry (NPR) [19](#cam4965-bib-0019){ref-type="ref"}. The NPR is a national population‐based database containing admission and discharge dates, combined with diagnoses classified according to ICD‐10.

### COPD diagnoses {#cam4965-sec-0009}

We identified patients as having COPD if they in the period 12--36 months before lung cancer diagnosis had either at least two redeemed prescriptions of relevant medicine, an inpatient visit (See appendix, Table [1](#cam4965-tbl-0001){ref-type="table-wrap"}, for the ICD10 codes for the inpatient visit) or at least two lung function tests performed in general practice [20](#cam4965-bib-0020){ref-type="ref"}. The medicine included the following ACT codes: R03AC, R03AK, R03BA, R03BB, R03CC, R03DA, R03DC, and V03AN01 (oxygen).

###### 

Characteristics of the 34,017 incident lung cancer patients and the 340,170 comparison subjects

                                       Women    Men     All                                                                             
  ------------------------------------ -------- ------- --------- ------- -------- ------- --------- ------- -------- ------- --------- -------
  Total                                15,655   46.0%   156,550   46.0%   18,362   54.0%   183,620   54.0%   34,017           340,170   
  Age                                                                                                                                   
  40--52                               1317     8.4%    13,129    8.4%    1000     5.5%    10,018    5.5%    2317     6.8%    23,147    6.8%
  53--64                               4514     28.8%   45,175    28.9%   5001     27.2%   50,099    27.3%   9515     28.0%   95,274    28.0%
  65--76                               6432     41.1%   64,371    41.1%   8074     44.0%   80,840    44.0%   14,506   42.6%   145,211   42.6%
  77--90                               3392     21.7%   33,875    21.6%   4287     23.3%   42,663    23.2%   7679     22.6%   76,538    22.6%
  Country of origin                                                                                                                     
  Danish                               15,172   96.9%   148,764   95.0%   17,550   95.6%   175,226   95.4%   32,722   96.2%   323,990   95.2%
  Immigrant/descendant (Western)       357      2.3%    4348      2.8%    410      2.2%    4115      2.2%    767      2.3%    8464      2.5%
  Immigrant/descendant (non‐Western)   126      0.8%    3438      2.2%    402      2.2%    4278      2.4%    528      1.5%    7716      2.3%
  Marital status                                                                                                                        
  Married/cohabitating                 6799     43.4%   77,584    49.5%   10,780   58.7%   118,393   64.5%   17,579   51.7%   195,977   57.6%
  Living alone                         7157     45.7%   61,976    39.6%   5664     30.9%   46,046    25.1%   12,821   37.7%   108,022   31.8%
  Unknown                              1699     10.9%   16,990    10.9%   1918     10.4%   19,181    10.4%   3617     10.6%   36,171    10.6%
  Education                                                                                                                             
  Basic                                9285     59.3%   75,282    48.1%   7942     43.3%   67,866    37.0%   17,227   50.6%   143,148   42.1%
  Short                                4573     29.2%   53,011    33.9%   8063     43.9%   82,883    45.1%   12,636   37.1%   135,894   40.0%
  Long                                 1267     8.1%    22,220    14.2%   1463     8.0%    25,022    13.6%   2730     8.0%    47,242    13.9%
  Unknown                              530      3.4%    6037      3.8%    894      4.8%    7849      4.3%    1424     4.3%    13,886    4.0%
  Labor market affiliation                                                                                                              
  Working                              3068     19.6%   37,114    23.7%   3777     20.6%   47,291    25.8%   6845     20.1%   84,405    24.8%
  Unemployed                           228      1.5%    1862      1.2%    331      1.8%    2036      1.1%    559      1.6%    3898      1.1%
  Retirement pension                   12,029   76.8%   114,341   73.0%   13,864   75.5%   131,491   71.6%   25,893   76.1%   245,833   72.3%
  Other                                330      2.1%    3233      2.1%    390      2.1%    2801      1.5%    720      2.2%    6034      1.8%
  Income                                                                                                                                
  Low                                  3665     23.4%   31,606    20.2%   4374     23.8%   35,190    19.1%   8039     23.6%   66,796    19.6%
  Middle                               8745     55.9%   78,870    50.4%   10,085   54.9%   89,395    48.7%   18,830   55.4%   168,265   49.5%
  High                                 3245     20.7%   46,074    29.4%   3903     21.3%   59,035    32.2%   7148     21.0%   105,109   30.9%
  Charlson comorbidity index score                                                                                                      
  0                                    8874     56.7%   115,787   74.0%   9752     53.1%   124,259   67.7%   18,626   54.8%   240,046   70.6%
  1                                    3544     22.6%   21,910    14.0%   4097     22.3%   29,464    16.0%   7641     22.5%   51,374    15.1%
  ≥2                                   3237     20.7%   18,853    12.0%   4513     24.6%   29,897    16.3%   7750     22.7%   48,750    14.3%
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### Lung cancer stage {#cam4965-sec-0010}

Information about stage was obtained from DCR and the DLCR. The pTNM was used if available. If the two registries differed in regard to the TNM stage, the DLCR was used. Stage at diagnosis was dichotomized into local and advanced disease. A cut‐point between stage IIB and IIIA was chosen since a previous study has documented a significant difference in mortality between these two stages [21](#cam4965-bib-0021){ref-type="ref"}. If any of the T or N values were missing, we categorized SCLC as limited if the tumor was M0 and as extensive if the tumor was M1 regardless of the values, known or unknown, of other components. We categorized NSCLC as advanced if the TNM stage included values of T4, N3, or M1, regardless of other components [22](#cam4965-bib-0022){ref-type="ref"}.

### Characteristics of study population {#cam4965-sec-0011}

Demographic and socioeconomic information was collected from Statistics Denmark. This included country of origin categorized into "Danish", "Immigrant/descendant from a Western country", or "Immigrant/descendant from a non‐Western country". Marital status 12 months prior to the diagnosis date was categorized into "living alone" or "cohabitating". Data on taxable income were extracted for the calendar year preceding the diagnosis date and categorized into three groups using the OECD‐modified scale: "Low" (the lowest 20%), "Middle" (the middle 50%), and "High" (the highest 30%)[23](#cam4965-bib-0023){ref-type="ref"}. The highest attained level of education was categorized into "Basic", "Short", "Long", and "Unknown" according to the international Standard Classification of Education [24](#cam4965-bib-0024){ref-type="ref"}. The Charlson Comorbidity Index (CCI) was used to account for comorbidity [25](#cam4965-bib-0025){ref-type="ref"}. The CCI was calculated on the basis of diagnoses registered in the NPR in a 10‐year‐period preceding the 12 months prior to the diagnosis date. We grouped the CCI into "Low" (CCI score = 0), "Moderate" (CCI score = 1--2), and "severe" (CCI score ≥3).

Statistical analysis {#cam4965-sec-0012}
--------------------

Odds ratios (ORs) for having a contact, a radiograph, a lung function test or a medicine prescription were calculated using conditional logistic regression, taking account of the matched design. Unconditional logistic regression analyses were made to compare lung cancer patient with local and advanced stage, and lung cancer patients with and without COPD. A negative binomial regression model applying cluster robust variance at practice level was used to calculate incidence rate ratios (IRRs) for comparisons of monthly rates of contacts, lung function tests, X‐rays, and prescriptions between lung cancer patients and the comparison group in the year before diagnosis.

Analyses were performed separately for each sex because of known differences in the use of general practice among men and women [26](#cam4965-bib-0026){ref-type="ref"}, [27](#cam4965-bib-0027){ref-type="ref"}. However, the estimates did not differ meaningfully between men and women, and are therefore presented combined (See appendix, Table 2 and Table 3, for separate analyses).

All analyses were adjusted for socioeconomic, demographic variables, age, and comorbidity. Data were analyzed using the statistical software Stata 13.0 (StataCorp LP, Texas, TX).

Ethics {#cam4965-sec-0013}
------

The study was approved by the Danish Data Protection Agency (j.no. 2009‐41‐3471).

Results {#cam4965-sec-0014}
=======

The study included 34,017 lung cancer patients and 340,170 comparison subjects. The study subjects were listed with 2676 general practices. Among the lung cancer patients 18.6% had localized disease (stage IA--IIB), 81.4% had advanced disease (stage IIIA--IV), and 0.7% of cases had no information on stage. A total of 7551 lung cancer patients (22.2%) were identified as having COPD compared to 11.9% in the comparison group.

The patients and comparison subjects differed according to socio‐demographic variables and comorbidity (Table [1](#cam4965-tbl-0001){ref-type="table-wrap"}). Lung cancer patients were more likely to be living alone and had lower income, lower education level, and higher comorbidity score. The mean age at diagnosis was 68 and 69 years for women and men, respectively.

During months 12 to 1 prior to diagnosis (i.e., omitting the last month before diagnosis), 92.6% of lung cancer patients and 88.4% of comparison subjects had one or more contacts to general practice (Table [2](#cam4965-tbl-0002){ref-type="table-wrap"}). The odds for having nine or more contacts were higher among lung cancers patients compared to comparison subjects (OR: 1.89 \[95 CI: 1.83--1.94\]) (Table [2](#cam4965-tbl-0002){ref-type="table-wrap"}). Lung cancer patients had significantly higher frequencies of GP contacts from four months prior to diagnosis and the differences rose consistently with a peak in the last month before diagnosis (Fig. [1](#cam4965-fig-0001){ref-type="fig"}A).

###### 

Proportion of persons with consultations, lung function tests, radiographs, Antibiotics prescriptions, and COPD medicine prescriptions during months 12 to 1 prior to lung cancer diagnosis

                        ALL study subjects   All lung cancers                                                                       
  --------------------- -------------------- ------------------ -------- ------- ------------------- ------ ------- ------- ------- -------------------
  Consultations                                                                                                                     
  0                     2507                 7.4%               46399    13.6%   0.42 (0.39--0.44)   544    8.7%    1903    6.9%    0.74 (0.65--0.83)
  1--4                  6980                 20.5%              98198    28.9%   0.68 (0.65--0.70)   1244   19.8%   5659    20.6%   0.99 (0.91--1.07)
  5--8                  6889                 20.3%              72491    21.3%   0.98 (0.95--1.01)   1250   19.9%   5602    20.4%   1.00 (0.93--1.08)
  ≥9                    17648                51.8%              123082   36.2%   1.89 (1.83--1.94)   3232   51.6%   14332   52.1%   1.09 (1.02--1.16)
  Lung function tests                                                                                                               
  0                     31500                92.6%              331855   97.5%   0.29 (0.27--0.30)   5787   92.3%   25473   92.6%   1.06 (0.94--1.18)
  1                     2342                 6.9%               7778     2.3%    3.44 (3.26--3.63)   451    7.2%    1880    6.8%    0.94 (0.84--1.06)
  ≥2                    175                  0.5%               537      0.2%    3.74 (3.08--4.55)   32     0.5%    143     0.6%    1.00 (0.66--1.52)
  Radiographs                                                                                                                       
  0                     23361                68.7%              300836   88.4%   0.28 (0.27--0.29)   3637   58.0%   19564   71.2%   1.89 (1.78--2.01)
  1                     6223                 18.3%              28051    8.3%    2.43 (2.35--2.52)   1443   23.0%   4734    17.2%   0.70 (0.65--0.75)
  ≥2                    4433                 13.0%              11283    3.3%    4.26 (4.08--4.45)   1190   19.0%   3198    11.6%   0.54 (0.50--0.59)
  Antibiotics                                                                                                                       
  0                     19410                57.1%              258900   76.1%   0.42 (0.41--0.43)   3345   53.4%   15919   57.9%   1.20 (1.13--1.28)
  1                     7527                 22.1%              52412    15.4%   1.54 (1.50--1.59)   1486   23.6%   5991    21.8%   0.90 (0.84--0.97)
  ≥2                    7080                 20.8%              28858    8.5%    2.70 (2.61--2.78)   1439   23.0%   5586    20.3%   0.86 (0.80--0.92)
  COPD prescriptions                                                                                                                
  0                     32462                95.4%              335382   98.6%   0.30 (0.28--0.32)   5979   95.4%   26239   95.4%   1.01 (0.87--1.16)
  ≥1                    1555                 4.6%               4788     1.4%    3.33 (3.12--3.55)   291    4.6%    1257    4.6%    0.99 (0.86--1.15)

OR, odds ratio; CI, confidence interval; CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease.

Adjusted analyses comparing the activity between lung cancer patients and comparison subjects. ^2^Adjusted analyses comparing the activity between lung cancer patients with localized disease and lung cancer patients with metastatic disease. ORs are adjusted for age, county of origin, marital status, education, labor market affiliation, income, and comorbidity (CCI).

251 patients without information about stage at diagnosis are omitted.
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![Contacts (A), X‐rays (B), lung function tests (C), chronic obstructive pulmonary disease (COPD) prescriptions (D), and antibiotics prescriptions (E) in general practice. Upper part: Mean numbers of contacts, lung function test, X‐rays, or prescriptions in general practice for lung cancer patients and matched comparison subjects prior to diagnosis/date with 95% confidence interval. Lower part: the incidence rate ratio (IRR) with 95% CIs.](CAM4-6-79-g001){#cam4965-fig-0001}

13.0% of the lung cancer patients and 3.3% of the comparisons had two or more radiographs performed during the 11 months before the last month before diagnosis (OR: 4.26 \[95% CI: 4.08--4.45\]) (Table [2](#cam4965-tbl-0002){ref-type="table-wrap"}). The rates were higher for lung cancer patients throughout all 12 months before diagnosis with a large excess just before diagnosis (Fig. [1](#cam4965-fig-0001){ref-type="fig"}B).

7.4% of the lung cancer patients and 2.5% of comparison subjects had one or more first‐time lung function test performed in general practice during the 11 months before diagnosis. During the 12 months before diagnosis the number of lung function test were significantly higher among lung cancer patients than among the comparisons (Fig. [1](#cam4965-fig-0001){ref-type="fig"}C) and the rates rose until peaking in the last month (IRR: 13.1 \[95% CI: 12.2--14.2\]).

During the last 11 months before the month before diagnosis, 20.8% of the lung cancer patients and 8.5% of the comparisons persons were treated with antibiotics twice or more (OR: 2.70 \[95% CI: 2.61--2.78\]) (Table [2](#cam4965-tbl-0002){ref-type="table-wrap"}). The higher number of antibiotic prescriptions was mainly seen in the last 4 months before diagnosis (Fig. [1](#cam4965-fig-0001){ref-type="fig"}E), during month 12 to 6 prior to diagnosis lung cancer patients were treated less with antibiotics than compared to the comparison subjects.

Furthermore, 4.6% of the lung cancer cases and 1.4% of the comparisons had one or more new prescription of COPD medicine (Table [2](#cam4965-tbl-0002){ref-type="table-wrap"}).

Lung cancer patients with localized disease versus advanced disease {#cam4965-sec-0015}
-------------------------------------------------------------------

8, 7% of lung cancer patients with localized disease had no contacts in general practice compared to 6.9% of patients with advanced disease (OR: 0.74 \[95% CI: 0.65--0.83\]) (Table [2](#cam4965-tbl-0002){ref-type="table-wrap"}) whereas the odds for having more contacts were similar between the two groups. 19.0% of patients with localized disease had two or more radiographs performed during the 11 months before diagnosis compared to 11.6% of patients with advanced disease (OR = 0.54 \[95% CI: 0.50--0.59\]). The use of lung function test in general practice and COPD prescriptions did not differ between patients with localized disease and patients with advanced disease, however, 23.0% of patients with localized disease and 20.3% of patients with advanced disease had two or more prescriptions of antibiotics (OR: 0.86 \[95% CI: 0.80--0.92\]).

Lung cancer patients with COPD versus other lung cancer patients {#cam4965-sec-0016}
----------------------------------------------------------------

Lung cancer patients with COPD had more contacts in the 11 months prior to diagnosis than lung cancer patients without COPD (OR: 2.06 \[95%CI: 1.93--2.19\]) and they also had higher odds of having lung function tests performed. Lung cancer patients with COPD had more contacts (≥9: OR: 1.52 \[95% CI: 1.43--1.62\]), more lung function tests (≥2 OR: 3.23 \[95% CI: 2.67--3.80\]), more X‐rays (≥2 OR: 2.23 \[95% CI: 2.07--2.40\]) and more prescriptions of antibiotics (≥2 OR: 1.93 \[95% CI: 1.82--2.05\]) than other COPD patients (Table [3](#cam4965-tbl-0003){ref-type="table-wrap"}). The difference in diagnostic activity was higher when comparing lung cancer patients and comparison subjects without COPD than when comparing lung cancer patients and comparisons diagnosed with COPD. 11% of lung cancer patients without COPD and 2.6% of comparisons without COPD had two or more X‐rays performed 12 to 1 months before diagnosis (OR: 4.19 \[95% CI: 3.98--4.41\]).

###### 

Proportion of patients with consultations, lung function tests, radiographs, Antibiotics prescriptions during months 12 to 1 prior lung cancer diagnosis

                        All lung cancers   with COPD   without COPD                                                                                                                   
  --------------------- ------------------ ----------- -------------- ------- ------------------- ------ ------- ------- ------- ------------------- ------- ------- -------- ------- -------------------
  Consultations                                                                                                                                                                       
  0                     178                2.4%        2329           8.8%    0.35 (0.29--0.42)   178    2.4%    1313    4.0%    0.63 (0.52--0.76)   2329    8.8%    40083    14.6%   0.49 (0.46--0.52)
  1--4                  799                10.6%       6181           23.4%   0.50 (0.46--0.55)   799    10.6%   5478    16.6%   0.63 (0.58--0.69)   6181    23.4%   83155    30.3%   0.73 (0.70--0.75)
  5--8                  1217               16.1%       5672           21.4%   0.78 (0.72--0.84)   1217   16.1%   6554    20.0%   0.79 (0.73--0.85)   5672    21.4%   59135    21.5%   1.06 (1.02--1.80)
  ≥9                    5359               70.9%       12284          46.4%   2.06 (1.93--2.19)   5359   70.9%   19510   59.4%   1.52 (1.43--1.62)   12284   46.4%   92229    33.6%   1.74 (1.69--1.80)
  Lung function tests                                                                                                                                                                 
  0                     6624               87.7%       24605          93.0%   0.40 (0.39--0.46)   6624   87.7%   31384   95.5%   0.34 (0.32--0.37)   24605   93.0%   263397   95.9%   0.85 (0.80--0.90)
  1                     612                8.1%        1730           6.5%    1.29 (1.16--1.44)   612    8.1%    1026    3.1%    2.69 (2.40--3.01)   1730    6.5%    7680     2.8%    1.45 (1.31--1.59)
  ≥2                    315                4,1%        131            0.5%    6.35 (5.92--6.99)   315    4.2%    445     1.4%    3.23 (2.67--3.80)   131     0.5%    3525     1.3%    0.50 (0.36--0.65)
  Radiographs                                                                                                                                                                         
  0                     4384               58.0%       18977          71.7%   0.71 (0.67--0.75)   4384   58.0%   24483   74.5%   0.48 (0.46--0.51)   18977   71.7%   247448   90.1%   0.27 (0.26--0.28)
  1                     1635               21.7%       4588           17.3%   1.15 (1.07--1.23)   1634   21.7%   5218    15.9%   1.37 (1.28--1.46)   4588    17.3%   20040    7.3%    2.69 (2.59--2.80)
  ≥2                    1532               20.3%       2901           11.0%   1.49 (1.39--1.61)   1532   20.3%   3154    9.6%    2.23 (2.07--2.40)   2901    11.0%   7114     2.6%    4.19 (3.98--4.41)
  Antibiotics                                                                                                                                                                         
  0                     2973               39.4%       16437          62.1%   0.42 (0.39--0.44)   2973   39.4%   18177   55.3%   0.53 (0.50--0.57)   16437   62.1%   215667   78.5%   0.45 (0.43--0.46)
  1                     1784               23.6%       5743           21.7%   1.08 (1.01--1.16)   1784   23.6%   7289    22.2%   1.05 (0.99--1.13)   5743    21.7%   40174    14.6%   1.62 (1.57--1.68)
  ≥2                    2794               37.0%       4286           16.2%   2.85 (2.67--3.04)   2794   37.0%   7389    22.5%   1.93 (1.82--2.05)   4286    16.2%   18761    6.8%    2.59 (2.48--2.69)

OR, odds ratio; CI, confidence interval; COPD, chronic obstructive pulmonary disease.

Adjusted analyses comparing the activity between patients with COPD and patients without COPD (first set of columns) and comparing activity between lung cancer patients and comparison subjects (the next two sets of columns). ORs are adjusted for age, county of origin, marital status, education, labor market affiliation, income, and comorbidity (CCI).
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In order to estimate the clinical relevance of the observed excess of general practice use we calculated risk estimates in the form of positive predictive values (PPVs). We calculated PPVs for having ≥9 contacts, ≥1 lung function test, ≥2 X‐rays, and ≥2 medicine prescriptions, also stratified by COPD. All PPVs calculated were below 1% (0.3% for ≥9 contacts to 0.9% for ≥2 X‐rays). These low PPVs are in range with many symptoms for lung cancer [11](#cam4965-bib-0011){ref-type="ref"}.

Discussion {#cam4965-sec-0017}
==========

This study, including 34,017 Danish lung cancer patients, found a higher frequency of contacts, diagnostic tests, and prescriptions in general practice for lung cancer patients compared with a comparison group, with a steep increase before the month prior to diagnosis. There was no important difference in activity when dividing the lung cancer patients into localized and advanced disease at diagnosis which indicates that they might present with similar symptoms although patients with advanced lung cancer had fewer radiographs before diagnosis than patients with local cancers. When dividing the study group according to COPD, the difference in activity between lung cancer patients and comparisons where more pronounced in the group without COPD. This indicates that having COPD can mask symptoms of lung cancer.

Strengths and limitations {#cam4965-sec-0018}
-------------------------

The strength of this study was a high statistical precision owing to the large, national study population. All data were collected from nationwide Danish registers. Cancer patient data were included from The Danish Cancer Registry and the Danish Lung Cancer Registry in order to have an almost complete inclusion of patients and clinical data [15](#cam4965-bib-0015){ref-type="ref"}, [16](#cam4965-bib-0016){ref-type="ref"}, [17](#cam4965-bib-0017){ref-type="ref"}. The information on healthcare services provided in primary care is considered to be valid as registration of these services forms the basis for remuneration of the GPs [17](#cam4965-bib-0017){ref-type="ref"}. By matching lung cancer patients and comparison persons according to age, gender, and general practice we diminished the risk of confounding. However, the results may have been influenced by confounding by smoking as we were not able to obtain smoking history, and there may be residual confounding by comorbidity as CCI does not include diseases managed only in general practice.

In the analyses of general practice activity we omitted the last month before diagnosis to eliminate the inevitable increase in activity just before diagnosis. Furthermore, we omitted patients\' lung function tests and prescriptions if they had such tests in the months between 12 and 36 before diagnosis. Test and prescriptions included in the analyses where therefore first‐time, reflecting the GPs response to the symptoms of the patients seen in practice at that time. Thus we predominantly explored new episodes of symptoms or signs where the GPs response would be a lung function test or prescription of medicine.

A limitation of the study was the lack of information on other lung diseases such as asthma, these diseases will increase GP contact rate and would probably be uneven distributed with a higher incidence among patients with lung cancer. However, a large proportion of these patients would have been in an ongoing follow‐up for the disease and they would have had lung function tests and prescriptions for medication in years before diagnosis. These tests would therefore have been omitted in the analyses. A further limitation of this study was a lack of information on the reasons for the consultations with the GPs.

We restricted our analyses to first occurrence of cancer to avoid the influence of an increased awareness of the GP among patients with a history of cancer. Being population based and thus including all lung cancer patients make the findings generalizable to other relevant health care systems.

Excess consultations among the lung cancer patients was also found in Danish study mapping the routes to diagnosis of lung cancer patients [12](#cam4965-bib-0012){ref-type="ref"} and a UK study of consultations before diagnosis [28](#cam4965-bib-0028){ref-type="ref"}.

The fact that lung cancer patients are seen in general practice before diagnosis and that the GP acts on the contacts with a high range of treatment and diagnostic activity months before diagnosis (even when omitting the last month) can be based on two things (or both things combined); either the GPs suspects cancer but fails to make the one diagnostic test to find the cancer (or fails to refer timely to fast‐track) or the GP do not suspect cancer by interpreting the symptoms as something else. The latter is supported by the increased use of lung function tests, antibiotics, and COPD medication. A Danish study found that comorbidity delayed diagnosis in around 23% of lung cancer patients seen by GPs [29](#cam4965-bib-0029){ref-type="ref"}. Symptoms like cough, weight loss, or breathlessness may be ascribed to known comorbidity rather than lung cancer. This is in line with our findings.

Many of the lung cancer patients had two or more X‐rays performed prior to diagnosis which is in line with results from a Danish study mapping the routes to diagnosis [12](#cam4965-bib-0012){ref-type="ref"}. For patients with localized disease this excess of X‐rays was more pronounced. This could be based on false negative X‐rays which occur in as much as a quarter of cancer patients [30](#cam4965-bib-0030){ref-type="ref"}, [31](#cam4965-bib-0031){ref-type="ref"}.

Patients with advanced disease had more contacts to general practice than patients with localized disease. This could be patients, with localized disease, bypassing general practice, and getting the diagnosis in connection with a hospital inpatients visit for other diseases and thus having an earlier lung cancer diagnosis.

We found virtually no difference in activity between patients with localized disease and advanced disease. A British study from 2015 found no difference in symptoms presented in general practice according to stage at diagnosis [32](#cam4965-bib-0032){ref-type="ref"}. However, the difference we did find (more X‐rays in the group of patients with localized disease) may be rooted in the X‐rays poor sensitivity, especially for small tumors.

The results, on the other hand, indicate an opportunity to optimize the early detection of lung cancer in general practice. So the question remains, how to select patients for further examination. GP awareness could be relevant as a Danish study from 2014 suggests that providing GPs with a short update on lung cancer (early symptoms, how to refer timely) would make the GPs refer more patients to examinations [33](#cam4965-bib-0033){ref-type="ref"}. Earlier and faster diagnosis may also be achieved by granting GPs free, direct access to low‐dose computed tomography; this would provide them with a more sensitive test for lung cancer than the X‐rays.

Conclusion {#cam4965-sec-0019}
==========

The findings of this large population‐based study revealed an increase in healthcare seeking and diagnostic activity in general practice among lung cancer patients prior to their diagnosis. This was not modified by the stage of the cancer but by whether the patients had COPD or not. Overall, the results indicate that a "diagnostic time window" is present, in which there is opportunity to diagnose lung cancer more timely in general practice. The high number of repeated X‐rays, lung function tests, and prescription of lung medicine and antibiotics show that GPs start investigating the patient\'s months before the diagnosis. The results support Continuing Medical Education for GPs and indicate a need for more studies on how to select patients for further diagnostic test and which test may be the most optimal in general practice.
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